MedTrace Logo

Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?

NCT04517175 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-08-18

No results posted yet for this study

Summary

Ki-67 is used as a marker for determination of the proliferative activity in solid tumors. The use within hemato-oncological malignancies is limited. This is related to limited technical possibilities of flow cytometry in the past. Meanwhile, flow cytometry in hemato-oncological malignancies has progressed to assessment of 8 colors and makes it possible to add Ki-67 as an additional marker to the 8-color panels. Adding Ki-67 to these panels could lead to improved diagnosis and prediction of therapy response for a number of hemato-oncological malignancies.

Conditions

Interventions

DIAGNOSTIC_TEST

Flow cytometry

Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67.

Sponsors & Collaborators

  • Zuyderland Medisch Centrum

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • Maastricht University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2025-09-01
Completion
2025-09-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04517175 on ClinicalTrials.gov